Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + Ivosidenib or Enasidenib in Relapsed/Refractory AML with FLT3/IDH Mutations
NCT05756777Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Adverse Events at 1 year. Started Oct 2023; status: active, not recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05756777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756777.